- Home
- SBI vs CHRS Comparison
SBI vs CHRS Comparison
Compare SBI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBI
- CHRS
- Stock Information
- Founded
- SBI 1992
- CHRS 2010
- Country
- SBI United States
- CHRS United States
- Employees
- SBI N/A
- CHRS N/A
- Industry
- SBI Finance/Investors Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SBI Finance
- CHRS Health Care
- Exchange
- SBI Nasdaq
- CHRS Nasdaq
- Market Cap
- SBI 111.5M
- CHRS 100.9M
- IPO Year
- SBI N/A
- CHRS 2014
- Fundamental
- Price
- SBI $8.02
- CHRS $1.10
- Analyst Decision
- SBI
- CHRS Strong Buy
- Analyst Count
- SBI 0
- CHRS 4
- Target Price
- SBI N/A
- CHRS $6.13
- AVG Volume (30 Days)
- SBI 39.5K
- CHRS 3.3M
- Earning Date
- SBI 01-01-0001
- CHRS 11-06-2024
- Dividend Yield
- SBI 4.52%
- CHRS N/A
- EPS Growth
- SBI N/A
- CHRS N/A
- EPS
- SBI N/A
- CHRS N/A
- Revenue
- SBI N/A
- CHRS $304,340,000.00
- Revenue This Year
- SBI N/A
- CHRS $3.33
- Revenue Next Year
- SBI N/A
- CHRS $16.77
- P/E Ratio
- SBI N/A
- CHRS N/A
- Revenue Growth
- SBI N/A
- CHRS 44.19
- 52 Week Low
- SBI $6.96
- CHRS $0.66
- 52 Week High
- SBI $8.00
- CHRS $3.70
- Technical
- Relative Strength Index (RSI)
- SBI 42.61
- CHRS 69.14
- Support Level
- SBI $8.01
- CHRS $0.70
- Resistance Level
- SBI $8.07
- CHRS $0.89
- Average True Range (ATR)
- SBI 0.06
- CHRS 0.11
- MACD
- SBI 0.00
- CHRS 0.05
- Stochastic Oscillator
- SBI 26.67
- CHRS 86.27
About SBI Western Asset Intermediate Muni Fund Inc
Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.